ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 310,76
-0,03%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. PainReform Ltd (PRFX)

  7. PainReform Ltd (PRFX) Actualités

PRFX

PainReform (PRFX)

PainReform Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PRFX
DateHeureSourceTitreSymboleSociété
31/05/202422h24Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PRFXPainReform Ltd
31/05/202422h15GlobeNewswire Inc.PainReform Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:PRFXPainReform Ltd
15/05/202422h05GlobeNewswire Inc.PainReform Provides Business Update for the First Quarter of 2024NASDAQ:PRFXPainReform Ltd
08/05/202414h30GlobeNewswire Inc.PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.comNASDAQ:PRFXPainReform Ltd
18/04/202420h19GlobeNewswire Inc.PainReform Announces Closing of $4 Million Public OfferingNASDAQ:PRFXPainReform Ltd
16/04/202414h00GlobeNewswire Inc.PainReform Announces Pricing of $4 Million Public OfferingNASDAQ:PRFXPainReform Ltd
09/04/202415h00GlobeNewswire Inc.PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing ConditionsNASDAQ:PRFXPainReform Ltd
02/04/202414h30GlobeNewswire Inc.PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in BunionectomyNASDAQ:PRFXPainReform Ltd
01/03/202422h34Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:PRFXPainReform Ltd
01/03/202414h00GlobeNewswire Inc.PainReform Provides Year-End Business UpdateNASDAQ:PRFXPainReform Ltd
29/02/202422h37Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:PRFXPainReform Ltd
22/01/202414h30GlobeNewswire Inc.PainReform to Present at the Microcap Conference in Atlantic CityNASDAQ:PRFXPainReform Ltd
22/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRFXPainReform Ltd
19/01/202422h30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PRFXPainReform Ltd
12/01/202422h15Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:PRFXPainReform Ltd
03/01/202414h30GlobeNewswire Inc.PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain ReliefNASDAQ:PRFXPainReform Ltd
27/12/202300h00GlobeNewswire Inc.PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross ProceedsNASDAQ:PRFXPainReform Ltd
15/11/202322h05GlobeNewswire Inc.PainReform Provides Business Update for the Third Quarter of 2023NASDAQ:PRFXPainReform Ltd
11/09/202314h30GlobeNewswire Inc.PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master FileNASDAQ:PRFXPainReform Ltd
07/09/202316h00GlobeNewswire Inc.PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, HungaryNASDAQ:PRFXPainReform Ltd
05/09/202314h30GlobeNewswire Inc.PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York CityNASDAQ:PRFXPainReform Ltd
10/08/202322h05GlobeNewswire Inc.PainReform Provides Business Update for the Second Quarter of 2023NASDAQ:PRFXPainReform Ltd
19/07/202315h00GlobeNewswire Inc.PainReform Regains Compliance with Nasdaq Continued Listing RequirementsNASDAQ:PRFXPainReform Ltd
18/07/202317h59Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PRFXPainReform Ltd
14/07/202320h35GlobeNewswire Inc.PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private PlacementNASDAQ:PRFXPainReform Ltd
12/07/202315h05GlobeNewswire Inc.PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private PlacementNASDAQ:PRFXPainReform Ltd
15/06/202314h30GlobeNewswire Inc.PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21stNASDAQ:PRFXPainReform Ltd
07/06/202322h30GlobeNewswire Inc.PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryNASDAQ:PRFXPainReform Ltd
18/05/202315h11Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PRFXPainReform Ltd
18/05/202315h00GlobeNewswire Inc.PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy SurgeryNASDAQ:PRFXPainReform Ltd
 Showing the most relevant articles for your search:NASDAQ:PRFX

Dernières Valeurs Consultées

LSE
44LP
Bk. America 48
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés